942307-80-4

Usage

Type of Compound

Chemical compound

Usage

Commonly used in organic synthesis

Structure

A derivative of azetidine, a four-membered nitrogen-containing heterocycle

Contains

Tert-butoxycarbonyl (Boc) protecting group, methoxy and methyl group

Utilization

Often utilized as a building block in the synthesis of various pharmaceuticals, agrochemicals, and other organic compounds

Significance

Unique structure and reactivity make it a valuable tool in medicinal chemistry and drug discovery

Application

Can be used for the creation of diverse molecular scaffolds and the modification of existing compounds

Boc Protecting Group

Can be selectively removed under mild conditions, making it a versatile precursor for the synthesis of complex molecules

Upstream product

• 398489-26-4 tert-butyl 3-oxoazetidine-1-carboxylate 
• 1104083-23-9 tert-butyl 3-hydroxy-3-methylazetidine-1-carboxylate 
• 74-88-4 methyl iodide 
• 24424-99-5 di-tert-butyl dicarbonate 
• 168144-41-0 1-(diphenylmethyl)-3-methoxy-3-methylazetidine 

Downstream Products

• 877665-31-1 3-methoxy-3-methylazetidine 

Relevant academic research and scientific papers

As the NS4B inhibitor benzofuran analogs (by machine translation)

The present invention discloses a kind of as NS4B benzofuran analogue inhibitors, in particular to the formula (I) below or a pharmaceutically acceptable salt thereof. (by machine translation)

HEPATITIS C INHIBITOR COMPOUNDS

Compounds of Formula (I) wherein R1, R2, R3, R4 and R5 are defined herein, maintain good activity against NS3 proteases containing clinically relevant genotype 1a R155K and genotype 1b D168V resistance mutations. The compounds are useful as inhibitors of HCV NS3 protease for the treatment of hepatitis C viral infection.

VLA-4 INHIBITORY DRUG

There is provided a VLA-4 inhibitory drug having good oral absorbability and exhibiting sufficient anti-inflammatory effects when administered orally. A compound represented by the following formula (I): wherein R1 represents a hydrogen atom or a C1-8 alkyl group; R2 represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group, orabenzyloxygroupwhichmaybe substituted; Q represents a monocyclic or bicyclic nitrogen-containing heterocyclic group which may be substituted, and has a nitrogen atom as the bonding site; Y represents an oxygen atom or CH2; W represents a bicyclic aromatic hydrocarbon ring group which may be substituted, or a bicyclic aromatic heterocyclic group whichmaybe substituted; R3a, R3b and R3c each independently represent a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group; and A1 represents a nitrogen atom or C-R3d (wherein R3d represents a hydrogen atom, a halogen atom, a C1-8 alkoxy group or a C1-8 alkyl group), or a salt thereof, or a VLA-4 inhibitory drug comprising the compound or the salt as an active ingredient.